Hematology
Multiple Myeloma
Our Multiple Myeloma drug test helps oncologists navigate the complexity of treatment selection by generating patient-specific drug sensitivity profiles from a bone marrow aspirate. Built on our proprietary PrevisionOne™ platform and rooted in clinically validated pharmacoscopy, the test systematically evaluates approved drugs and combinations—including proteasome inhibitors, IMiDs, corticosteroids, and advanced immunotherapies—on both cancer and healthy cells. Within an average turnaround of 72 hours, it provides actionable, functional data that supports evidence-based decisions, enabling oncologists to identify the most effective therapies for each individual patient and optimize disease control in this increasingly complex therapeutic landscape.
Hematology
Acute Myeloid Leukemia
Our Acute Myeloid Leukemia drug test helps oncologists rapidly identify the therapies most likely to be effective for each patient. Using blood draws or bone marrow aspirates, PrevisionOne™ evaluates patient-derived malignant and healthy cells against a broad range of AML-relevant therapies, generating functional, patient-specific response data rooted in clinically validated pharmacoscopy. We currently offer two AML drug screening panels which can be selected based on the patient’s profile and the desired treatments and treatment combinations. With a fast, 72-hour turnaround, the test provides actionable insights that support evidence-based, personalized treatment decisions in this aggressive and heterogeneous disease, helping clinicians optimize outcomes and improve survival.
Our Glioblastoma drug test helps oncologists rapidly identify the most effective therapies ex vivo - directly on primary patient samples. PrevisionOne™ evaluates responses to an extensive panel of drugs and combinations designed to reach the brain, generating functional, patient-specific data rooted in clinically validated pharmacoscopy. With a five-day turnaround time, the test provides actionable insights that support evidence-based treatment decisions in this highly aggressive and heterogeneous disease, helping clinicians optimize therapy selection and improve patient outcomes.
